Literature DB >> 21499215

Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway.

Satoshi Watanabe1, Takashi Kishimoto, Osamu Yokosuka.   

Abstract

OBJECTIVES: Escape from anoikis, apoptosis induced by loss of cell-cell or cell-extracellular matrix interactions, is important in tumor invasion and metastasis. Hepatocyte growth factor (HGF) is known to play a pivotal role in pancreatic carcinomas. This study aimed to determine the antianoikis effect of HGF in pancreatic carcinoma cells.
METHODS: Antianoikis effect of HGF was evaluated in human pancreatic carcinoma cells in nonadherent culture with or without anti-E-cadherin antibody. Signal pathways were investigated by Western blot analysis and inhibition assay using inhibitors for phosphatidylinositol 3-kinase and p38.
RESULTS: Pancreatic carcinoma cells underwent anoikis in nonadherent culture. However, some of the carcinoma cells survived by forming aggregations in suspension. Anti-E-cadherin antibody dissociated the aggregations, and the separated cells underwent additional anoikis. Hepatocyte growth factor inhibited anoikis irrespective of E-cadherin-mediated cell-cell contact. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway abolished the antianoikis effect of HGF. Phosphorylation of Akt was induced by HGF, and the phosphorylated Akt persisted even when E-cadherin was inhibited.
CONCLUSIONS: Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway in which activation of Akt may be involved. It is thus supposed that HGF may have a potent role in invasion and metastasis of pancreatic carcinoma cells by exerting its antianoikis effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499215     DOI: 10.1097/MPA.0b013e318214fa6c

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

Review 1.  Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells.

Authors:  Wojciech Błogowski; Tomasz Bodnarczuk; Teresa Starzyńska
Journal:  Stem Cells Transl Med       Date:  2016-05-23       Impact factor: 6.940

2.  Anoikis resistance: an essential prerequisite for tumor metastasis.

Authors:  Yong-Nyun Kim; Kyung Hee Koo; Jee Young Sung; Un-Jung Yun; Hyeryeong Kim
Journal:  Int J Cell Biol       Date:  2012-02-23

Review 3.  Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge.

Authors:  Wasia Rizwani; Amanda E Allen; Jose G Trevino
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

4.  Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.

Authors:  Cahuê De Bernardis Murat; Paula Waki Lopes da Rosa; Maria Angela Henriques Zanella Fortes; Luciana Corrêa; Marcel Cerqueira Cesar Machado; Estela Maria Novak; Sheila Aparecida Coelho Siqueira; Maria Adelaide Albergaria Pereira; Maria Lucia Corrêa-Giannella; Daniel Giannella-Neto; Ricardo Rodrigues Giorgi
Journal:  Diabetol Metab Syndr       Date:  2015-10-01       Impact factor: 3.320

5.  Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions.

Authors:  Véronique Pomerleau; Mélissa Landry; Jimmy Bernier; Pierre H Vachon; Caroline Saucier
Journal:  BMC Cancer       Date:  2014-04-04       Impact factor: 4.430

6.  Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Andrew V Biankin; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Br J Cancer       Date:  2016-01-14       Impact factor: 7.640

7.  Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Neil Merrett; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Oncotarget       Date:  2017-09-11

8.  Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells.

Authors:  Bin Sun; Congli Hu; Zhibin Yang; Xiaofeng Zhang; Linlin Zhao; Junye Xiong; Junyong Ma; Lei Chen; Haihua Qian; Xiangji Luo; Lehua Shi; Jun Li; Xianshuo Cheng; Zhengfeng Yin
Journal:  Oncotarget       Date:  2017-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.